KYOWA KIRIN CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public, Subsidiary

Established: 1949-07-01

Employees: 5.9K

Market Cap: -

Website: http://www.kyowa-kirin.co.jp

Clinical Trials

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: granisetron

First Posted Date: 2009-04-30

Last Posted Date: 2024-06-17

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT00890565

Locations: 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Phase 1

Completed

Conditions: Peripheral T-Cell Lymphoma

Interventions: Biological: KW-0761

First Posted Date: 2009-04-28

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT00888927

Locations: 🇺🇸
Stanford Medical Center, Stanford, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States

and more 2 locations

PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV Granisetron

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: granisetron

First Posted Date: 2009-04-01

Last Posted Date: 2024-06-17

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT00873197

Locations: 🇬🇧
Charles River Clinical Services Edinburgh Ltd, Edinburgh, United Kingdom

An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: granisetron

First Posted Date: 2009-03-25

Last Posted Date: 2024-07-24

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT00868764

Locations: 🇬🇧
Charles River Clinical Services Edinburgh Ltd, Edinburgh, United Kingdom

A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes, Type 2

Interventions: Drug: placebo
Drug: saxagliptin

First Posted Date: 2009-03-06

Last Posted Date: 2017-03-09

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 350

Registration Number: NCT00857558

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer

Interventions: Biological: KRN330
Drug: Irinotecan

First Posted Date: 2009-02-06

Last Posted Date: 2024-04-26

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 65

Registration Number: NCT00838578

Locations: 🇺🇸
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
University of Florida COllege of Medicine/Shands Cancer Center, Gainesville, Florida, United States

and more 9 locations

A Study of KRN23 in X-linked Hypophosphatemia

Phase 1

Completed

Conditions: X-linked Hypophosphatemia

Interventions: Drug: KRN23
Drug: Placebo

First Posted Date: 2009-01-28

Last Posted Date: 2024-06-17

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT00830674

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Duke Clinical Research Unit, Durham, North Carolina, United States
🇺🇸
General Clinical Research Center, Indiana University School of Medicine, Indianapolis, Indiana, United States

and more 1 locations

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia (AML)

Interventions: Drug: KW-2449

First Posted Date: 2008-10-24

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT00779480

Locations: 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
St. Francis Hospital, Greenville, South Carolina, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 1 locations

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: BIW-8962

First Posted Date: 2008-10-20

Last Posted Date: 2024-04-25

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 23

Registration Number: NCT00775502

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Taussig Cancer Center- Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

and more 2 locations

A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

Phase 3

Completed

Conditions: Pain, Cancer

Interventions: Drug: KW-2246 (fentanyl citrate)
Drug: Placebo

First Posted Date: 2008-05-26

Last Posted Date: 2020-08-28

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 51

Registration Number: NCT00684632

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy